Biofrontera (Germany)

Recent papers from Biofrontera (Germany)

1. Seasonal and Geographic Trends in Photodynamic Therapy and Cryosurgery Use in the United States: A Cross-sectional Study From 2015-2022.2026
2. Red light photodynamic therapy with 10% aminolevulinic acid gel showed efficacy for treatment of superficial basal cell carcinoma in a randomized, vehicle controlled, double-blind, multicenter phase III studyJournal of the American Academy of Dermatology · 2025
3. Long‐term follow‐up of a randomized, double‐blind, phase III, multi‐centre study to evaluate the safety and efficacy of field‐directed photodynamic therapy (PDT) of mild to moderate actinic keratosis using BF‐200 ALA versus placebo and the BF‐RhodoLED® lampJournal of the European Academy of Dermatology and Venereology · 2024
4. Effective treatment of actinic keratosis on the hands with red light photodynamic therapy using BF-200 ALAPhotodiagnosis and Photodynamic Therapy · 2024
5. Diagnosis and Management of Pediatric Psoriasis: An Overview for PediatriciansJournal of Drugs in Dermatology · 2023
6. Loss of parkin causes endoplasmic reticulum calcium dyshomeostasis by upregulation of reticulocalbin 1European Journal of Neuroscience · 2023
7. Field Therapy for Actinic Keratosis: A Structured Review of the Literature on Efficacy, Cost, and AdherenceDermatologic Surgery · 2023
8. Streamlining Culture Conditions for the Neuroblastoma Cell Line SH-SY5Y: A Prerequisite for Functional StudiesMethods and Protocols · 2022
9. Identification and pharmacological modification of resistance mechanisms to protoporphyrin-mediated photodynamic therapy in human cutaneous squamous cell carcinoma cell linesPhotodiagnosis and Photodynamic Therapy · 2022
10. PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1Scientific Reports · 2019
11. Somatic mutations in kinetochore gene KNSTRN are associated with basal proliferating actinic keratoses and cutaneous squamous cell carcinomaJournal of the European Academy of Dermatology and Venereology · 2019
12. A randomized, intraindividual, non‐inferiority, Phase III study comparing daylight photodynamic therapy with BF ‐200 ALA gel and MAL cream for the treatment of actinic keratosisJournal of the European Academy of Dermatology and Venereology · 2018
13. A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapyENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2018
14. Patient‐reported health outcomes in patients with non‐melanoma skin cancer and actinic keratosis: results from a large‐scale observational study analysing effects of diagnoses and disease progressionJournal of the European Academy of Dermatology and Venereology · 2017
15. A randomized, double‐blind, phase III , multicentre study to evaluate the safety and efficacy of BF ‐200 ALA (Ameluz ® ) vs. placebo in the field‐directed treatment of mild‐to‐moderate actinic keratosis with photodynamic therapy (PDT) when using the BF ‐Rhodo LED ® lampBritish Journal of Dermatology · 2016
16. Long‐term (6 and 12 months) follow‐up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF‐200 ALA and methyl aminolaevulinate for the treatment of actinic keratosisBritish Journal of Dermatology · 2012
17. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placeboBritish Journal of Dermatology · 2011
18. Genetic mouse models for Parkinson's disease display severe pathology in glial cell mitochondriaHuman Molecular Genetics · 2011
19. Parkin Directly Modulates 26S Proteasome ActivityJournal of Neuroscience · 2010
20. Upregulation of cathepsin S in psoriatic keratinocytesExperimental Dermatology · 2009